Introduction
Optimization and safety of gene transfer is presently a challenge in gene therapy approaches. In particular, it can be useful to coexpress two or more genes of interest, in the case of heterodimeric proteins such as interleukin 12, when a resistance gene must be coexpressed, or to combine therapeutic molecules with a synergistic effect as reported for antitumoral antiangiogenesis. 1, 2 Gene coexpression is also useful in the case of monogenic inherited diseases: coexpression of insulin-like growth factor 1 or antimyostatin with microdystrophin or calpain 3, respectively, appears as an attractive strategy to improve the gene therapy of myopathies. 3, 4 Among the possibilities to obtain such a coexpression, one can use either two separate vectors or a single vector expressing two transcription units. However, these approaches can lead to transgene silencing, especially if the gene product shows toxicity. 5 Another approach is based on the use of internal ribosome entry sites (IRES), structural RNA elements that allow the translation machinery to be recruited within the mRNA, while the dominant pathway of translation initiation recruits ribosomes on the mRNA capped 5 0 end. 6, 7 IRESs can therefore be used to design expression cassettes coding for several genes from a single transcription unit. 5, 8 Such genes encoded by the same mRNA are called 'cistrons' and the corresponding mRNA is 'bi-or multicistronic. ' The first IRESs were discovered in 1988 in picornaviruses 9 and currently, most available bicistronic vectors contain the IRES from the encephalomyocarditis virus (EMCV). 10 This IRES is indeed very efficient in transiently transfected cells and has a higher activity than the poliovirus IRES in human embryonic stem cells. 11 Retroviral IRESs have also been successfully utilized in the construction of high-titer retroviral vectors. 12 In addition, several IRESs with distinct features and properties have been described in cellular mRNAs. 7, 13 Several of them are shorter than the EMCV IRES and more flexible with regards to the distance between the IRES and the initiation codon.
14 These cellular IRESs have often been reported as having a lower activity than the EMCV IRES in cell transfection assays. Yet these comparisons do not necessarily reflect physiological situations and we have previously shown that in transgenic mice cellular IRESs can display tissue-specific activities, in contrast to the EMCV IRES. 15 In addition, measurements of IRES activities after plasmid electrotransfer into mouse skeletal muscle have revealed that the IRES from the fibroblast growth factor 1 (FGF-1) mRNA leader A is as active as the EMCV IRES.
14 Furthermore, in a tricistronic context, the FGF-2 IRES induces the expression of exogenous cDNA in human melanoma cells without any positive or negative regulation from the other IRES present in the vector, in contrast to EMCV or HTLV-1 IRES. 16 The use of IRESs for an optimized gene transfer seems particularly adequate in conditions of stress. Indeed, in unstressed conditions, IRES-dependent translation has often been described as less efficient than cap-dependent translation. It is the opposite in conditions of stress where the cap-dependent translation is blocked, whereas the IRES-dependent translation is maintained or enhanced. Interestingly, several cellular IRESs have been shown to be specifically activated by several stress conditions such as apoptosis, hypoxia or amino-acid starvation. 17, 18 We have recently shown that the vascular endothelial growth factor (VEGF) and FGF-2 IRESs, but not EMCV IRES, are activated in vivo in conditions of leg ischemia. This suggests that cellular IRESs are good candidates to control gene expression in different pathological conditions targeted by gene therapy, such as muscle atrophy, ischemia, tumor hypoxia and apoptosis.
These observations indicate that the cellular IRESs may be valuable elements for the design of improved multicistronic vectors. The FGF-1 IRES, which can be reduced to a size of about 100 nt, is interesting in this respect, especially for a use in viral vectors where the size of the transgene expression cassette is limited.
14 Adeno-associated virus (AAV) derived vectors are highly effective for stable gene transfer in a number of tissues, including skeletal muscle, liver, retina and brain where long-lasting expression of therapeutic transgenes have been obtained in pre-clinical and human clinical studies. 19, 20 AAV particles have a low packaging capacity and the size of sequences inserted into the vectors is strictly limited to less than 5 kb. 21, 22 In this context, the use of short IRESs seems very attractive.
Adeno-associated virus vectors are particularly efficient for stable gene transfer into the skeletal muscle and are therefore actively explored for the development of gene therapy for myopathies. 23 Alternatively, the muscle can be engineered into a platform able to synthesize therapeutic proteins. These proteins may be secreted into the circulation and distributed throughout the organism, as shown for blood clotting factors or lysosomal enzymes. 24, 25 They may also act locally as illustrated in the pro-angiogenic approaches designed to combat lower-limb ischemia. 26 In the present study, we designed two AAV-derived bicistronic vectors, using the FGF-1 IRES A (called FGF-1 IRES in the text) or the EMCV IRES. In our analysis, we have used two luciferase genes as reporter genes, the Renilla luciferase (Luc R) as a first cistron, and the firefly luciferase (Luc F), as a second cistron under the control of the IRES. The results show that the FGF-1 IRES, although less efficient than the EMCV IRES in 911 retinoblast culture, allows a higher rate of translation of the second cistron in C2C12 myoblasts and when the vector is administered into the skeletal muscle. In addition, the presence of the FGF-1 IRES in the bicistronic mRNA results in enhanced expression of the transgene in myoblasts as well as in skeletal muscle.
Results
The FGF-1 IRES A allows a high and stoechiometric bicistronic transgene expression in mouse myoblasts
To test the FGF-1 IRES A in the context of an AAV vector, two bicistronic cassettes with either the FGF-1 or the EMCV IRES were introduced into the conventional pGG2 AAV2 vector plasmid downstream from the cytomegalovirus promoter, between the AAV inverted terminal repeats (Figure 1a) . The first cistron, translated in a cap-dependent manner, codes for Luc R, whereas the second cistron whose translation is IRES-dependent, codes for Luc F. . The MOI of 10 2 did not allow us to conclude, as Luc F was hardly detectable. As observed previously with plasmids transfected in the same cell line, the activity of the FGF-1 IRES was about three to four times lower to that of the EMCV IRES (Figure 1c ). 14, 15 C2C12 mouse myoblasts were transduced by the same virions. Transduction was less efficient than with 911 cells: an MOI of 10 5 was necessary to obtain a detectable luciferase expression (Figure 2a) . Here, again transgene expression was proportional to the MOI and the Luc F to Luc R stoechiometry remained constant. However, in contrast to 911 cells, the FGF-1 IRES activity in C2C12 myoblasts was three fold superior to that of EMCV IRES (Figure 2b) .
One can notice that in both cell types, the Luc R activity is superior (two times in 911 and four times in C2C12) with the vector containing the FGF-1 IRES (Figures 1b and 2a) . Real-time reverse transcription-PCR quantification of Luc R and Luc F mRNAs revealed that the bicistronic mRNA with the FGF-1 IRES was two times more abundant than that containing the EMCV IRES (Figures 1d and 2c) . The similar amount of Luc R and Luc F mRNAs measured for each vector confirmed that the mRNAs were bicistronic.
These data indicate that the bicistronic AAV vectors containing the EMCV or FGF-1 IRES are functional in expressing both reporter genes with a stable stoechiometry. Furthermore, the FGF-1 IRES activity is higher in C2C12 myoblasts.
AAV-mediated transgene expression in vivo is at least 10 times more efficient with the FGF-1 IRES than with the EMCV IRES The FGF-1-and EMCV-based bicistronic rAAVs were injected into the tibialis anterior muscle of BALB/C mice (n ¼ 4; see Materials methods) and a kinetics of Luc R and Luc F expression was measured in muscle extracts during 28 days. As shown in Figures 3a and b , expression increased with time for the two vectors, reaching a plateau at day 8. A slight increase was still detected at day 28. Surprisingly, the two vectors, although expressed at the same level at day 2, showed very distinct expression profiles: at day 8, expression of AAV-derived bicistronic vector with the FGF-1 IRES A Delluc-Clavières et al both cistrons was 10 times superior with the vector containing the FGF-1 IRES, than with the vector containing the EMCV IRES. However, the IRES activity presented as the ratio Luc F/Luc R was not significantly different for the two vectors ( Figure 3c ).
These data showed that both EMCV and FGF-1 IRESs have a similar activity in mouse muscle, but that the presence of the FGF-1 IRES results in a 10-fold increase in overall transgene expression. In all cases, the stoechiometry was kept constant.
To confirm these data, animals were injected with rAAVs as above, and luciferase expression was followed on live animals, using a CCD bioluminescence camera. Luc F was measured during 120 days ( Figure 4a ) and quantified (Figures 4b and c) . This approach, which allows a much lower standard error, clearly confirmed the data obtained in Figure 3 . Here, the difference was still higher, Luc F being 20-30 times more efficiently expressed in the presence of the FGF-1 IRES, compared to the EMCV IRES.
The CCD camera only allowed us to detect the IRESdriven Luc F expression. Thus, a quantitative analysis was performed at day 120 on muscle extracts, in which luciferase activities, RNA and cDNA levels were measured ( Figure 5 ).
As expected, both Luc F and Luc R were about 10 times more expressed with the FGF-1 IRES (Figure 5a ). The values of the IRES activities were 3.6 and 6.7 for the EMCV and FGF-1 IRESs, respectively ( Figure 5b ). Quantitative reverse transcription-PCR measurements of RNAs clearly showed that both Luc F and Luc R mRNAs were 10 times more abundant with the FGF-1 IRES than with the EMCV IRES, whereas the DNA was only two times more abundant (Figures 5c and d) . These data were identical with independent rAAV productions (data not shown). Furthermore, for each vector, the Luc R and Luc F mRNAs were present in the same amount, confirming that the mRNA is bicistronic.
In conclusion, a bicistronic AAV-derived vector containing the FGF-1 IRES allows an efficient long-term expression of a bicistronic luciferase transgene, with a stable stoechiometry. The vector expression obtained in the presence of the FGF-1 IRES is 10 times higher than that obtained in the presence of the EMCV IRES, indicating that this cellular IRES is an efficient tool to be used for gene transfer into the skeletal muscle.
Discussion
In this study, we have analyzed the expression of two AAV-derived bicistronic vectors, containing either the classically used EMCV IRES, or the more recently discovered FGF-1 IRES.
14 Our data clearly show that the presence of the FGF-1 IRES in the vector allows gene transfer to occur with an efficiency that is at least 10 times superior to that obtained with a similar vector containing the EMCV IRES. This observation identifies Several questions are raised by our data. An interesting point is the higher activity of the FGF-1 IRES in murine C2C12 myoblasts and in mouse muscle as compared with human 911 embryonic retinoblasts. Such a difference is not likely to result from species specificity, as we have used the human IRES sequence in our vector. Furthermore, our previous study has shown a high conservation of the FGF-1 IRES A secondary structure and function in mammals.
14 Our data suggest that the FGF-1 IRES is muscle specific. The FGF-1 IRES activity would require specific IRES trans-acting factors (ITAFs) to work efficiently, as shown for other cellular IRESs. These ITAFs, which would be present and active in muscle but not in 911 retinoblasts, remain to be identified. 28, 29 The IRES regulation by different ITAFs may be an important parameter to take into account, when designing multicistronic vectors, to avoid interferences between IRES elements that can impair translation efficiency. 16, 30 The most striking observation of our study is that the presence of the FGF-1 IRES enhances the expression of both cistrons, whereas it would be expected to affect expression of the second cistron exclusively. The vector containing the FGF-1 IRES is two times more efficient than the vector with the EMCV IRES in 911 cells, four times more efficient in C2C12 and 10-20 times more efficient in mouse muscle. To understand the mechan- 
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A Delluc-Clavières et al ism(s) responsible for these differences, we analyzed the level of bicistronic mRNA by quantitative reverse transcription-PCR and the presence of transgene DNA in cells by qPCR. In both 911 and C2C12 cells, the level of bicistronic mRNA was two times superior for the FGF-1 IRES vector (Figures 1d and 2c) , whereas its level was 10 times superior in vivo, compared with the EMCV vector (Figure 5c ). DNA quantification indicated that the FGF-1 IRES vector DNA was two times more abundant than EMCV vector DNA both in vitro and in vivo, although the same number of rAAV particle genomes, quantified by qPCR, were used for transduction (Figure 5d and data not shown). This was reproduced with two independent rAAV productions. These data indicate that several distinct mechanisms may be responsible for the high efficiency of rAAV transduction in the presence FGF-1 IRES.
One among the possible mechanisms is the stimulation of first cistron translation due to the presence of the FGF-1 IRES. Although the ratio of second versus first cistron expression is generally used as a measure of IRES activity, a recent report indicates that picornavirus IRESs are able to enhance translation of the first cistron in a bicistronic mRNA. 31 The current explanation is that whenever eIF-4F has been captured to a dicistronic mRNA by binding the IRES via eIF-4G, it can be provided in cis to the 5 0 end of the mRNA and thus stimulate translation initiation of the first cistron. In our case, this mechanism can explain the stimulation of the FGF-1 IRES vector expression in C2C12 cells, where the first cistron expression does not follow the mRNA level in contrast to 911 cells. The FGF-1 IRES, being more active than the EMCV IRES in myoblasts, would recruit more efficiently eIF-4F and thus stimulate the first cistron expression in these cells.
This mechanism may also occur in vivo, in mouse muscle, but cannot fully account for the observed activation of transgene expression. Indeed, our quantitative reverse transcription-PCR data indicate an increase in bicistronic mRNA accumulation, which is not related 
A Delluc-Clavières et al to the DNA accumulation. This suggests that some element in the FGF-1 IRES may also affect the mRNA transcription or stability. The presence of an enhancer in the IRES cDNA remains an interesting possibility. Alternatively, the presence of an RNA-stabilizing element in the FGF-1 IRES or of a destabilizing element in EMCV IRES cannot be ruled out. Presently, no information is available in the literature, on a possible effect of IRESs on mRNA stability. However a study reports that the embryonic lethal abnormal visual mRNA stability factor HuR interacts with the 5 0 leader of the insulin-like growth factor-IR transcript, and blocks the IRES activity. 32 It is not reported whether HuR can act on the mRNA stability through this interaction. However ITAFs have been shown to affect the stability of the IRES structure: the ITAFs unr and nPTB act as RNA chaperones by changing the structure of the APAF-1 IRES into one that permits translation initiation. 29 In addition, p53, which is able to inhibit the FGF-2 IRES activity, also acts by modifying the RNA structure. 33 Thus, we can hypothesize that ITAFs may also act on mRNA stability: if the mRNA is highly structured, it may presumably render it more resistant to RNAses. p53 is probably not responsible for the FGF-1 IRES inhibition in 911 cells, as these cells express the adenovirus E1 protein that complexes and inactivates p53.
Only a few published studies make use of an AAVderived vector to coexpress genes of interest, probably due to the transgene size limitation. Successful examples include the coexpression of anti-atherogenic ApoAI with lecithine acetyltransferase 34 or the prevention of tumor progression in experimental gliomas after thymidine kinase and interleukin-2 coexpression. 35 In both studies, the EMCV IRES was used. Our data suggest that the EMCV IRES is far from being optimal for gene coexpression in vivo, and that the use of a cellular IRES could be beneficial.
Materials and methods

Recombinant vectors
The plasmids used in this study to generate recombinant AAV viruses have been already described. 14, 15 Briefly, the expression cassette contains 'Luc R-IRES-Luc F' under the control of the cytomegalovirus promoter and the simian virus 40 polyA signal. The IRES sequence was of viral (EMCV) or cellular origin (FGF1-A). A chimeric intron of human b-globin origin was introduced between cytomegalovirus promoter and the first cistron to allow increased expression. These two cassettes have been introduced into the pGG2 vector, which contains inverted terminal repeat sequences. Pseudotyped AAV vectors were generated by packaging AAV2-based recombinant genomes in AAV1 capsids. Adenovirus-free ). Two days after transduction, cells were collected, lysed in 100 ml of lysis buffer and tested for their luciferase activity using a luminometer (Centro LB960, Berthold, Thoiry, France) and the Dual-Luciferase Reporter Assay (Promega, Charbonnières-Les-Bains, France), according to the manufacturer's instructions. In a similar way, the C2C12 mouse myoblast cell line (ATCC number: CRL-1772) was transduced with AAV vectors at two MOI (100 000 and 200 000) and tested for their luciferase activities after 3 days. Bicistronic mRNA quantification was done in both cell lines. RNA extractions were performed using the GenElute Mammalian Total RNA kit (Sigma-Aldrich, St Quentin, France). For reverse transcription and real-time PCR, see section 'Bicistronic mRNA quantification with real-time PCR.' Mice Six-week old female BALB/c J@Rj were purchased from Janvier laboratories. They were housed in the animal facility of IFR31 Institute (Toulouse, France) and cared for in conformity with the guidelines of the company's local Ethics Committee.
In vivo tibialis anterior mouse muscle transduction with rAAV vectors
Mice were anesthetized by intraperitoneal injection of Ketamine (125 mg kg À1 body weight) and Xylazine (10 mg kg À1 body weight) solution. Bicistronic AAV vectors were injected intramuscularly using an Insulin syringe (300 U, Myjector U-100 insulin, Terumo, provided by Dutscher, Brumath, France). The number of particles was of 5.15 10 E +9 particles in 25 ml final volume for the first in vivo experiment (see Figure 3) and of 1.57 10 E +10 particles in the same volume for the second in vivo experiment (see Figure 4) .
Quantification of Luc R and Luc F activities from muscle lysates using a luminometer Two days after rAAV transduction (and up to 120 days), mice were anesthetized, and tibialis anterior muscle was removed, stored at À80 1C and then ground in Passive Lysis Buffer (Promega) using an Ultra-Turrax T25 (Janke and Kunkel, IKA labortechnik, Stanfen, Germany). Quantification of ex vivo bioluminescence was achieved with a luminometer (Centro LB960, Berthold) using the Dual-Luciferase Reporter Assay (Promega), according to the manufacturer's instructions.
Raw data were obtained from the MicroWin 2000 software. Mean control value (corresponding to non transduced muscle) was subtracted from each sample value. Results were then expressed either in RLU s À1 of counting or in RLU per mg of total protein.
Quantification of total protein amount in mouse muscle lysates
The total protein amount in muscle lysates was assayed using the Dc Protein Assay (BioRad Marnes-LaCoquette, France). Briefly, 20 ml of S reagent was mixed with 1 ml of A reagent to obtain the A 0 reagent. A 25 ml volume of this A 0 mix was added to 1 ml of the sample in a 96-well plate (Nunclon) and 200 ml of B reagent was then added. After 10 min incubation time, the OD was read at 690 nm. In parallel, a BSA standard curve was plotted to determine the total protein amount in each sample.
In vivo imaging and quantification of bioluminescence data
In vivo imaging was performed using a system consisting of a cooled CCD camera (cooled to À80 1C) mounted on a dark box chamber, a camera controller, a camera cooling system and a computer system for data acquisition and analysis (deep cooling BTW 512 S/N, camera 1394 ORCA II, Hamamatsu Photonics, Mossy, France).
Mice were first transduced with bicistronic AAV2-1 vectors containing either the EMCV or FGF1-A IRES sequence to express the Luc F. After 2 days (and up to 120 days), mice were anesthetized by intraperitoneal injection of Ketamine (12.5 mg ml À1 ) and Xylazine (1%) solutions (10 mg g À1 body weight), and mice legs were depilated using a depilation cream (Veet). Mice were then injected by intraperitoneal way with D-luciferin (50 mg g À1 BW, Luciferin-EF Promega France), and after 5 min incubation time, they were placed in the dark box chamber.
The photon emission, emitted from mice, was measured. The gray scale images and bioluminescence color images were superimposed using the Simple PCI software (Hamamatsu Photonics). Light output from specified regions of interest was quantified as the total number of photons emitted per second of time exposure and per region of interest.
Bicistronic mRNA quantification with real-time PCR
At 120 days post-transduction, tibialis anterior muscles were isolated, plunged in nitrogen liquid and stored at À80 1C. The frozen muscles were pulverized using a BioPulverizer (0.1-1 g tissue capacity, 59013N, Biospec Products Inc., Bartlesville, OK, USA) previously cooled thoroughly with liquid nitrogen. The resulted tissue powder was next divided in several parts to extract native luciferase proteins and RNA from the same sample.
Total RNA was purified using the RNeasy mini kit (Qiagen, Courtaboenf, France), according to the manufacturer's recommendations. An additional DNaseI treatment (RNase-free DNase set, Qiagen, Courtabocal, France) was carried out. Reverse transcription was performed using 2 mg total RNA and the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA).
Specific primers and probes for Renilla luciferase and Luc F cDNA were designed using Taqman Primer and Probe Design of Primer Express software (Applied Biosystems). The sequences of primers are available upon request. Primers were purchased from Invitrogen and 5 0 6-FAM, 3 0 MGB probes from Applied Biosystems. Quantification of ribosomal 18S RNA was used as an internal control with specific primers using Sybr Green AAV-derived bicistronic vector with the FGF-1 IRES A Delluc-Clavières et al technology (Applied Biosystems). The reaction assay mix contained 10 ng of cDNA, primers (300 nM), probes (200 nM) and the Taqman universal PCR master mix (Applied Biosystems) for luciferase sequences amplification; and 5 ng of cDNA, primers (300 nM) and the Sybr Green master mix (Applied Biosystems) for 18S amplification. The reaction assay was performed on Gene Amp 7900HT sequence detection system and results were treated with the SDS 2.2.2 software (Applied Biosystems).
AAV transgene DNA quantification with real-time PCR DNA extraction from mice muscular extracts was performed using the NucleoSpin Tissue kit (MachereyNagel), according to the manufacturer's instructions. The amount of bicistronic transgene DNA was measured by real-time PCR using specific probes for each cistron (one probe in Luc F cistron and one probe in Luc R-see the section above). Results were normalized by mouse glyceraldehyde-3-phosphate dehydrogenase gene level for each sample. The reaction assay was performed on Gene Amp 7900HT sequence detection system and results were treated with the SDS 2.2.2 software (Applied Biosystems).
Statistical analysis
Statistical analysis has been performed using the program Prism (GraphPad Software Inc.). Two-way ANOVA tests with BonFerroni post-tests were realized to compare luciferase activities and transgene levels in real-time PCR experiments.
